bioAffinity Technologies (BIAF) Stock Analysis & Winston Score

bioAffinity Technologies is a small diagnostics company working on better ways to detect lung cancer early. Its lead product, CyPath Lung, is a lab test that analyzes cells from a simple lung wash sample to help doctors identify cancer before it becomes harder to treat. The company focuses on patients who are at high risk for lung cancer, such as long-time smokers. bioAffinity generates revenue by selling its diagnostic test through its CLIA-certified laboratory. The company is based in San Antonio, Texas, and operates primarily in the United States. It is a micro-cap company still in an early commercial stage, with negative margins as it spends heavily on research and sales efforts relative to its small revenue base. The key growth driver is broader adoption of CyPath Lung as a companion to CT screening, but the main risk is that the company must significantly scale revenue to reach profitability while managing limited cash resources.